(Q42596400)

3 November 2017

0 references

Pure red cell aplasia as first manifestation of splenic marginal zone lymphoma-successful treatment with rituximab: a case report (English)

1 reference

3 November 2017

1 reference

Athanasios Anastasiadis

1

1 reference

3 November 2017

Dimitrios Margaritis

2

1 reference

3 November 2017

Ioannis Kotsianidis

3

1 reference

3 November 2017

Emmanouil Spanoudakis

4

1 reference

3 November 2017

Anna Christoforidou

5

1 reference

3 November 2017

Ioannis Kostopoulos

6

1 reference

3 November 2017

Constantinos Tsatalas

7

1 reference

3 November 2017

18 August 2009

1 reference

3 November 2017

1 reference

3 November 2017

2

1 reference

3 November 2017

6913

1 reference

Acquired pure red cell aplasia: updated review of treatment

3 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769326

Rituximab monotherapy is highly effective in splenic marginal zone lymphoma

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769326

Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769326

Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769326

Pure red cell aplasia—a rare disease with multiple causes

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769326

28 May 2018

Pure red cell aplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769326

Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769326

Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2769326

Splenic lymphoma presenting as warm autoimmune hemolytic anemia associated with pure red cell aplasia

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19918496

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19918496

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rituximab monotherapy for splenic marginal zone lymphoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19918496

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4076/1757-1626-2-6913

1 reference

Dimensions Publication ID

3 November 2017

0 references

1 reference

3 November 2017

PubMed publication ID

19918496

1 reference